Introduction
Ventilator-associated pneumonia (VAP) is a well-established cause of morbidity and mortality. Reference Franchineau, Luyt, Combes and Schmidt1,Reference Biffi, Di Bella and Scaravilli2 Current VAP research and National Health Safety Network (NHSN) definitions exclude patients on extracorporeal membrane oxygenation (ECMO). Reference Spalding, Cripps and Minshall3 As use of ECMO grows, Reference Brodie, Abrams and MacLaren4 we must recognize and prevent pneumonia in this population. A meta-analysis reported ECMO-associated pneumonia occurred in 24.4 cases/1000 ECMO days, Reference Biffi, Di Bella and Scaravilli2 and smaller studies report an incidence of 55-74% in ECMO patients. Reference Franchineau, Luyt, Combes and Schmidt1 Without an agreed-upon definition, many studies used diagnostic criteria for VAP to approximate pneumonia in ECMO.
Traditional diagnostic criteria for VAP may be unreliable in ECMO patients. Reference Abrams, Grasselli, Schmidt, Mueller and Brodie5 First, they ignore important ECMO parameters: flow and sweep. During ECMO, blood is removed from the body, oxygenated and ventilated, then returned to the patient. To improve oxygenation, ECMO flow is increased. To improve ventilation, ECMO sweep is increased. Reference Makdisi and Wang6,Reference Wrisinger and Thompson7 Changes in these are important indicators of oxygenation and ventilation. Additionally, there is movement towards early weaning from mechanical ventilation for patients on ECMO, Reference Brodie, Abrams and MacLaren4,Reference Langer, Santini and Bottino8 making diagnostic criteria for possible ventilator-associated pneumonia (PVAP), such as FiO2 and PEEP values, obsolete. Reference Spalding, Cripps and Minshall3 Traditional signs of infection may be unreliable, as the extracorporeal circulation can mask fever and confound systemic inflammatory markers. Reference Franchineau, Luyt, Combes and Schmidt1,Reference Millar, Fanning, McDonald, McAuley and Fraser10 Finally, chest radiography, incorporated in some definitions, Reference Schmidt, Brechot and Hariri9 may be subjective and limited in patients with acute respiratory distress syndrome (ARDS) or chest trauma requiring VV ECMO.
We must consider new diagnostic criteria for ECMO-associated pneumonia (EAP) to promote quality, document outcomes, and allow research. In this study, we perform a retrospective analysis to assess current NHSN PVAP definitions as diagnostic criteria for pneumonia in ECMO. We propose new EAP criteria, incorporating inflammatory, microbiologic, and ECMO data. We then test the criteria’s ability to diagnose and predict pneumonia in a clinically adjudicated cohort of ECMO patients with pneumonia.
Methods
91 positive bronchoalveolar lavage (BAL) cultures from 52 ECMO patients between 2018 and 2021 were abstracted and reviewed for evidence of clinical pneumonia (CP). Cases were excluded when the organism does not typically cause pneumonia (Candida spp, Enterococcus spp), organism attributed to colonization, there is no documented antibiotic change, evidence of a severe concurrent non-pulmonary infection, a respiratory culture obtained <48 hours or >30 days after the ECMO starts, or the patient immunocompromised prior to cannulation. This led to the exclusion of 66 cultures from 32 patients. Included patients had positive BAL culture, concern for CP documented prospectively by the primary team, and antibiotic change reflective of diagnosis. Importantly, all cases were manually adjudicated by two authors to ensure agreement (JE, JW, RL). We considered the duration of active infection to be 5 days, with day 1 being the culture date.
Our proposed diagnostic criteria for EAP is build upon the established guidelines for PVAP but include parameters unique to ECMO populations. These criteria were developed based on literature review and clinical experience with ECMO patients.
In a patient on ECMO for ≥ 48 hours:
-
1. Worsening oxygenation, as evidenced by increase in daily minimum values of flow ≥ 10% in 24 hours or sweep ≥ 20% in 24 hours.
-
2. Evidence of inflammation or infection, demonstrated by temperature <36˚ C or >38˚C or leukocyte count <4k or >12k.
-
3. Positive culture data, including broncho-alveolar lavage (BAL) culture with >105 CFU or Endotracheal aspirate culture with >104 CFU of a pneumonia-causing organism.
Patients meeting criteria 1 + 2 were designated “Possible- EAP – Definition 1.” This definition excludes microbiological data. Patients with either criteria 1 + 3 or criteria 2 + 3 were designated “Possible EAP – Definition 2.” This definition includes microbiological data. Patients meeting all 3 criteria were designated “Confirmed EAP.”
Given the diverse causes of severe illness precipitating need for ECMO, each patient was used as their own control by reviewing all ECMO days post cannulation from day 3–30 (or decannulation if earlier). Clinical parameters were reviewed to determine if the patient met the established criteria for PVAP by NHSN criteria Reference Spalding, Cripps and Minshall3 or our proposed criteria for EAP.
We compared these criteria against the standard of culture-confirmed, clinically treated, and independently adjudicated clinical pneumonia (CP). Sensitivity and standard deviation were calculated for each set of diagnostic criteria. To assess the diagnostic accuracy of our criteria, we utilized receiver operating characteristic (ROC) analysis, computing the area under the curve (AUC), and the Mann–Whitney statistic to quantify the strength of association between predicted probabilities and actual outcomes.
Results
We identified 20 patients representing 505 ECMO days. Our population was 65% male, mean age 46.3 years. Most (85%) received VV ECMO. ECMO indications included COVID ARDS (50%), trauma or inhalational injury (25%), cardiac (20%), non-COVID ARDS (5%). BAL culture organisms included S. aureus (45%), Pseudomonas species (40%), Klebsiella species (15%), and single episodes of other typical hospital-acquired pneumonia organisms.
In 505 ECMO patient days, there were 25 CP events accounting for 112 days. Patients with CP only met criteria for PVAP 1% of the time (Figure 1), a sensitivity of 4.5% (AUC 0.52 [CI = 0.50, 0.54]). “Possible EAP – Definition 2” was the most effective model for predicting CP (sensitivity 91.1%, AUC 0.95 [CI = 0.93, 0.98]), followed distantly by the confirmed EAP model (sensitivity 19.6%) and Possible EAP-Definition 1 (19.6%) (Table 1). All 25 unique CP events met possible EAP -Definition 2 at some point during infectious window and 14/25 (56%) included increase in ECMO parameters.
Receiver operating characteristic analysis of the proposed diagnostic criteria for pneumonia to a clinically defined pneumonia cohort.
Sensitivity of EAP diagnostic criteria. Number of days with pneumonia calculated out of 505 total ECMO days studied.
The Mann–Whitney statistic suggests that the EAP model has a stronger relationship with true outcomes than the PVAP model. Furthermore, contrast estimation and testing results suggests that the estimated difference in AUC between EAP and PVAP models was 0.07 (standard error 0.02). The chi-square test for the contrast estimate was highly significant (P < 0.0001).
Discussion
This study suggests NHSN PVAP criteria are poor predictors of pneumonia in patients on ECMO. This is an important shift in our understanding, as previous research in this field has relied on NHSN PVAP criteria to study epidemiology and outcomes. We are the first group to propose incorporation of ECMO oxygenation parameters (flow and sweep) with infectious parameters and respiratory cultures – thresholds used in critically ill and mechanically ventilated patients. Moreover, we applied this to a population that was predominantly VV ECMO, the group traditionally considered most difficult to study these outcomes. We found this model to be sensitive in predicting pneumonia that was clinically treated in this population.
Without guidelines or definitions, we are unable to identify risk factors that may help prevent pneumonia in ECMO. Our criteria had a strong correlation with cases of pneumonia that were clinically diagnosed and treated. Although our criteria relied on culture data, which limits utility as a preventive tool, we must begin with reliable measures of disease state to understand the true incidence and risk factors.
This study is limited by the small sample size of highly complex patients chosen because of the outcome of interest. There is risk for confounding, particularly given many patients were on ECMO for a prolonged duration, likely due to the coinciding COVID-19 pandemic. We defined our infectious period beginning with time of confirmed infection to best capture infectious events, but further exploration is warranted to understand if predictive measures could be identified prior to infectious outcome. We believe our study supports the utility of modifying current definitions for VAP within critically ill patients by incorporating ECMO-specific parameters. Our work confirms the need for further study to demonstrate the viability of this criterion in a larger and more diverse ECMO cohort.
Financial support
None.
Competing interests
Dr. James Kirklin is director of Data Center for STS Intemacs/Pedimacs Registries (Director, partial salary support), and has ownership interest in Kirklin Solutions, Inc. Peggy Blood serves as a consultant for Medtronic. The other authors disclose no conflicts of interest.
Open access
